Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Structure Therapeutics Inc. chief scientific officer Xichen Lin exercised share options covering 23,634 Ordinary Shares at $0.34 per share, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS at weighted average prices of $50.7956 and $51.7088 per ADS under a Rule 10b5-1 trading plan entered into on March 26, 2026. Following these transactions, Lin holds 252,594 Ordinary Shares directly and options over 166,532 Ordinary Shares exercisable at $0.34 per share until September 10, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,878 shares ($401,629)
Net Sell
6 txns
Insider
Lin Xichen
Role
CHIEF SCIENTIFIC OFFICER
Sold
7,878 shs ($402K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (right to buy) | 23,634 | $0.00 | -- |
| Conversion | American Depositary Shares | 7,878 | $0.00 | -- |
| Sale | American Depositary Shares | 6,278 | $50.7956 | $319K |
| Sale | American Depositary Shares | 1,600 | $51.7088 | $83K |
| Exercise | Ordinary Shares | 23,634 | $0.34 | $8K |
| Conversion | Ordinary Shares | 23,634 | $0.00 | -- |
Holdings After Transaction:
Share Option (right to buy) — 166,532 shares (Direct);
American Depositary Shares — 7,878 shares (Direct);
Ordinary Shares — 252,594 shares (Direct)
Footnotes (1)
- Reflects price per share in Ordinary Shares. The Ordinary Shares were converted into American Depositary Shares as reported in Table II. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 23,634 Ordinary Shares. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. 23,634 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 7,878 American Depositary Shares. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026. Reflects price per share in American Depositary Shares. The weighted average sale price for the transaction reported was $50.7956 and the range of prices were between $50.31 and $51.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided. The weighted average sale price for the transaction reported was $51.7088, and the range of prices were between $51.32 and $52.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
Key Figures
Options exercised into Ordinary Shares: 23,634 Ordinary Shares
Option exercise price: 0.3400 $ per Ordinary Share
ADS sold: 7,878 American Depositary Shares
+5 more
8 metrics
Options exercised into Ordinary Shares
23,634 Ordinary Shares
Ordinary Shares acquired upon exercise of share option on July 14, 2026
Option exercise price
0.3400 $ per Ordinary Share
Exercise price for share option partially exercised on July 14, 2026
ADS sold
7,878 American Depositary Shares
Total ADS sold in open-market transactions on July 14, 2026
Weighted average sale price (ADS block 1)
50.7956 $ per ADS
Weighted average price for sale of 6,278 ADS, with prices between $50.31 and $51.30
Weighted average sale price (ADS block 2)
51.7088 $ per ADS
Weighted average price for sale of 1,600 ADS, with prices between $51.32 and $52.27
Ordinary Shares held after transactions
252,594 Ordinary Shares
Direct Ordinary Share holdings of Xichen Lin following July 14, 2026 transactions
Ordinary Shares underlying remaining options
166,532 Ordinary Shares
Number of Ordinary Shares remaining under share option after partial exercise
Option expiration date
2029-09-10
Expiration date of the share option with 0.3400 $ exercise price
Key Terms
Rule 10b5-1 trading plan, American Depositary Shares, Share Option (right to buy), weighted average sale price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $51.7088"
Vesting Commencement Date financial
"one year after July 22, 2019 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
What insider transactions did Structure Therapeutics (GPCR) CSO Xichen Lin report on July 14, 2026?
Xichen Lin exercised options for 23,634 Ordinary Shares at $0.34, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS in two open-market transactions, as well as updating remaining option holdings and share ownership.
How many Structure Therapeutics (GPCR) ADS did Xichen Lin sell and at what prices?
Lin sold a total of 7,878 American Depositary Shares, including 6,278 ADS at a weighted average price of $50.7956 and 1,600 ADS at a weighted average price of $51.7088 per ADS, with detailed price ranges disclosed for each transaction.
What are Xichen Lin’s holdings in Structure Therapeutics (GPCR) after these transactions?
After the reported transactions, Lin holds 252,594 Ordinary Shares of Structure Therapeutics directly and retains share options over 166,532 Ordinary Shares, all with an exercise price of $0.34 per share and an expiration date of September 10, 2029.
Were Xichen Lin’s sales of Structure Therapeutics (GPCR) ADS made under a Rule 10b5-1 plan?
Yes. The American Depositary Shares sold by Lin were disposed of pursuant to a Rule 10b5-1 trading plan that was entered into on March 26, 2026, indicating the sales were pre-arranged rather than discretionary market-timing decisions.